Covalon Technologies Ltd. specializes in researching, developing, and commercializing medical technologies across various global markets. The company boasts strong financial health with a high gross margin of 67.2% and a solid EBITDA margin of 29.7%, indicating effective cost management. However, despite these strengths, the market cap of $108.82M suggests potential undervaluation relative to its profitability. Additionally, the low debt-to-equity ratio of 0.05 highlights strong liquidity, but it may also indicate underutilization of leverage for growth. Overall, Covalon presents a compelling yet cautiously optimistic investment profile.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Operating margin expanded by 6.9pp, demonstrating strong operational leverage.
Both gross margin (+4.2pp) and operating margin (+6.9pp) are expanding simultaneously, indicating the company is scaling profitably.
Gross margin improvement of 4.2pp suggests operational efficiency gains.
Strong gross margin of 59.9% reflects healthy unit economics.
Operating cash flow surged 33.5% YoY, indicating strong cash generation capability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q3 (June 30, 2026)